10 Stocks With Easy 20-40% Gains

8. Metsera Inc. (NASDAQ:MTSR)

Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry.

This followed Novo Nordisk’s confirmation late last week that it submitted a new $8.5 billion offer to acquire Metsera Inc. (NASDAQ:MTSR), which was 16 percent higher than Pfizer’s $7.3 billion offer, despite the latter already securing Metsera’s approval for the merger last month.

Meanwhile, Pfizer said that it was preparing to sue Metsera Inc. (NASDAQ:MTSR) and Novo Nordisk for breaching the agreement.

“It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk,” Pfizer said.

“The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement,” it noted.

It can be learned that Pfizer earlier this year discontinued the clinical trial for its potential weight loss treatment, danuglipron, due to a case of potential drug-induced liver failure.

Last month, it announced plans to acquire Metsera Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases to establish a foothold in the said industry.